| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 11/25/1999 | CA2332771A1 Ionophore containing composition for modulating amyloidosis |
| 11/25/1999 | CA2332711A1 Use of derivatives of aryl(or heteroaryl)azolylcarbinols in the manufacture of a medicament for the treatment of neurogenic inflammation |
| 11/25/1999 | CA2332649A1 Solid preparations for oral administration of drugs relating to genes |
| 11/25/1999 | CA2332545A1 Novel particulate formulations |
| 11/25/1999 | CA2332531A1 Protease inhibitors |
| 11/25/1999 | CA2332505A1 Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders |
| 11/25/1999 | CA2332492A1 Protease inhibitors |
| 11/25/1999 | CA2332462A1 Aryl nitrone therapeutics for the treatment of inflammatory bowel disease |
| 11/25/1999 | CA2332444A1 Pharmaceutical composition comprising d-chiro-inositol for improving insulin sensitivity and glucose metabolism |
| 11/25/1999 | CA2332403A1 Anti-viral compounds |
| 11/25/1999 | CA2332398A1 Benzamide therapeutics for the treatment of inflammatory bowel disease |
| 11/25/1999 | CA2332328A1 Compositions comprising organic mono- or dinitrate for treating impotence |
| 11/25/1999 | CA2332316A1 Tetraisoquinololine derivatives as modulators of dopamine d3 receptors |
| 11/25/1999 | CA2332279A1 Carboxamide compounds, compositions, and methods for inhibiting parp activity |
| 11/25/1999 | CA2332272A1 Novel analogs of 16-hydroxyeicosatetraenoic acid |
| 11/25/1999 | CA2332253A1 Combination therapy for treatment of depression |
| 11/25/1999 | CA2332239A1 Fused tricyclic compounds which inhibit parp activity |
| 11/25/1999 | CA2332035A1 Amide therapeutics for the treatment of inflammatory bowel disease |
| 11/25/1999 | CA2331875A1 Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same |
| 11/25/1999 | CA2331823A1 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection |
| 11/25/1999 | CA2331756A1 Retroviral protease inhibiting compounds |
| 11/25/1999 | CA2331318A1 Compositions comprising 2-phenyl-indole compounds and estrogen formulations |
| 11/25/1999 | CA2329916A1 Potassium channel agonists |
| 11/25/1999 | CA2329914A1 Pyrazinone thrombin inhibitors |
| 11/25/1999 | CA2329877A1 Compositions for the treatment of hiv and other viral infections |
| 11/25/1999 | CA2329868A1 Compounds, screening methods, and uses involving anti-apoptotic genes and gene products |
| 11/25/1999 | CA2329530A1 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens |
| 11/25/1999 | CA2329252A1 Compositions and methods for topical delivery of oligonucleotides |
| 11/25/1999 | CA2329139A1 Hemorrhagic enteritis virus dna sequences, proteins encoded thereby and various uses thereof |
| 11/25/1999 | CA2329130A1 Compositions and methods for non-parenteral delivery of oligonucleotides |
| 11/25/1999 | CA2328699A1 Benzamide derivatives for the treatment of diseases mediated by cytokines |
| 11/25/1999 | CA2328603A1 Novel compositions comprising interleukin-18 and a chemotherapeutic agent |
| 11/25/1999 | CA2328596A1 Cytosine deaminase gene |
| 11/25/1999 | CA2327585A1 Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation |
| 11/25/1999 | CA2327299A1 Cabergoline and pramipexole for treating cns diseases, especially parkinson's disease |
| 11/25/1999 | CA2327100A1 Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives |
| 11/25/1999 | CA2272833A1 Novel histidine derivatives, process for its preparation and uses thereof |
| 11/24/1999 | EP0959076A1 Heteroarylperidines and piperazines and their use as antipsychotics and analgetics |
| 11/24/1999 | EP0959075A1 Heteroarylpiperidines and piperazines and their use as antipsychotics and analgetics |
| 11/24/1999 | EP0959074A2 Substituted pyrazoles as CRF antagonists |
| 11/24/1999 | EP0959071A1 1-Aryl-4-cycloalk(en)ylpyrazoles as antiparasitic agents |
| 11/24/1999 | EP0959069A1 A process for the preparation of 13-CIS-retinoic acid |
| 11/24/1999 | EP0958835A1 Preventive/remedy for frequent urination and urinary incontinence |
| 11/24/1999 | EP0958829A1 Use of a peptide compound in the treatment of systemic lupus erythematosus |
| 11/24/1999 | EP0958825A1 Synergistic composition of a non-digestible carbohydrate and an anti-cancer drug for use in the treatment of cancer |
| 11/24/1999 | EP0958824A2 Olanzapine (zyprexa) in combination with fluoxetine (prozac), lithium or anticonvulsant for therapy of refractory depression |
| 11/24/1999 | EP0958823A1 Azelastine hydrochloride-containing percutaneous preparation having good percutaneous absorbability and reduced skin irritation |
| 11/24/1999 | EP0958822A1 The ocular hypotensive active compositions |
| 11/24/1999 | EP0958821A1 Fat emulsion containing xanthine derivative |
| 11/24/1999 | EP0958820A1 Use of an imidazol derivative for the manufacture of a medicament for treating auto-immunodiseases |
| 11/24/1999 | EP0958819A1 Remedies/preventives for abnormal motions accompanying disorders in extrapyramidal system |
| 11/24/1999 | EP0958818A1 Glutathione reductase activity potentiator containing troglitazone |
| 11/24/1999 | EP0958817A1 Composition containing diarylalkane derivative as the active ingredient for treating or preventing pancreatitis |
| 11/24/1999 | EP0958816A2 Medicament for the treatment of diabetes mellitus as well as its subsequent disorders |
| 11/24/1999 | EP0958815A1 Secondary cataract inhibitor |
| 11/24/1999 | EP0958810A2 Use of salicylic acid for regulating skin wrinkles and/or skin atrophy |
| 11/24/1999 | EP0958364A1 Immunotherapy and improved vaccines |
| 11/24/1999 | EP0958361A1 Rath genes and polypeptides and methods for the treatment and diagnosis of immune disorders |
| 11/24/1999 | EP0958354A1 Thiomethylene group-containing aldehyde cysteine and serine protease inhibitors |
| 11/24/1999 | EP0958307A1 O-sulfated bacterial polysaccharides |
| 11/24/1999 | EP0958304A1 Nucleotide sequence encoding the cd33-like protein |
| 11/24/1999 | EP0958296A1 Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| 11/24/1999 | EP0958294A1 2-(1,2,4-triazole-1-yl)-1,3,4-thiadiazole derivatives having an effect on the c.n.s. and the heart |
| 11/24/1999 | EP0958293A1 Nanomolar, non-peptide inhibitors of cathepsin d |
| 11/24/1999 | EP0958290A1 1,4-dihydropyridin derivatives and their use in therapy |
| 11/24/1999 | EP0958289A1 Amino acid ester containing azole antifungals |
| 11/24/1999 | EP0958287A1 Sulfamide-metalloprotease inhibitors |
| 11/24/1999 | EP0958285A1 TRICYCLIC BENZO[e]ISOINDOLES AND BENZO[h]ISOQUINOLINES |
| 11/24/1999 | EP0958283A1 New compounds with hemoregulating effect |
| 11/24/1999 | EP0958282A1 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines |
| 11/24/1999 | EP0958280A1 Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same |
| 11/24/1999 | EP0958277A1 Nitric oxide synthase inhibitors |
| 11/24/1999 | EP0958275A1 Selective inhibitors of prostaglandin endoperoxide synthase-2 |
| 11/24/1999 | EP0957941A1 USE OF A MELANOMA DIFFERENTIATION ASSOCIATED GENE (mda-7) FOR REVERSING A CANCEROUS PHENOTYPE |
| 11/24/1999 | EP0957932A2 A method and composition for enabling passage through the blood-brain barrier |
| 11/24/1999 | EP0957929A1 Vascular endothelial growth factor (vegf) nucleic acid ligand complexes |
| 11/24/1999 | EP0957928A1 Plant extract compositions, method of preparation, and pharmaceutical compositions containing them |
| 11/24/1999 | EP0957927A1 Medical composition and use thereof for the manufacture of a topical barrier formulation, a uv-radiation absorbing formulation, or an antiviral, antifungal, or antiinflammatory formulation |
| 11/24/1999 | EP0957926A1 Oligonucleotide compositions and methods for the modulation of the expression of b7 protein |
| 11/24/1999 | EP0957925A1 Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine |
| 11/24/1999 | EP0957924A1 Certain phosphinyl derivatives useful as naaladase inhibitors |
| 11/24/1999 | EP0957923A1 Sulfonylurea-glitazone synergistic combinations for diabetes |
| 11/24/1999 | EP0957922A1 New treatment for joint inflammation |
| 11/24/1999 | EP0957921A1 METHOD OF PREVENTING NEURODEGENERATION AND COGNITIVE DYSFUNCTION USING 17$g(a)-DIHYDROEQUILENIN |
| 11/24/1999 | EP0957920A1 Reducing toxic effects of carboplatin using dithioethers |
| 11/24/1999 | EP0957918A1 Method of treating or inhibiting neutropenia |
| 11/24/1999 | EP0957917A1 Vitronectin receptor antagonists |
| 11/24/1999 | EP0957916A1 Methods and compositions for treating urinary incontinence using enantiomerically enriched (r)-clidinium |
| 11/24/1999 | EP0957915A1 Agent for inhibition of cytokine production and agent for inhibition of cell adhesion |
| 11/24/1999 | EP0957914A1 Formulation of 5-ht agonists |
| 11/24/1999 | EP0957913A1 N-linked sulfonamides of heterocyclic thioesters |
| 11/24/1999 | EP0957912A1 Pharmaceutical compounds |
| 11/24/1999 | EP0957911A1 HESPERIDIN AND HESPERETIN AS 3-HYDROXY-3-METHYLGLUTARYL CoA(HMG-CoA) REDUCTASE INHIBITOR |
| 11/24/1999 | EP0957910A2 Method of regulating the female reproductive system through angiogenesis inhibitors |
| 11/24/1999 | EP0957909A1 Use of nitric oxid synthase inhibitors for the treatment of diabetes |
| 11/24/1999 | EP0957908A1 Fibrinogen receptor antagonists |
| 11/24/1999 | EP0957907A1 Il-8 receptor antagonists |
| 11/24/1999 | EP0957906A1 Local anesthetic for external use |
| 11/24/1999 | EP0957904A2 Compositions comprising choline and use of choline to treat endotoxic shock |
| 11/24/1999 | EP0957903A1 Pharmaceutical compositions and methods |